Last reviewed · How we verify

NCT05559138

Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection

Completed Last updated 29 September 2022
What this trial tests

trial testing no intervention in COVID-19 in 260 participants. Completed in 1 August 2022.

Timeline
1 July 2022
Primary endpoint
31 July 2022
1 August 2022

Quick facts

Lead sponsorRenJi Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment260
Start date1 July 2022
Primary completion31 July 2022
Estimated completion1 August 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

RenJi Hospital

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By collecting the clinical data of hemodialysis patients with Omicron infection in RenJi Hospital from April 7, 2022 to June 10, 2022, the clinical characteristics of this population were analyzed. And to analyze the risk factors of different clinical outcomes according to the clinical outcome of this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other RenJi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05559138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing